Our preliminary review of data in cBioportal (cbioportal.org) indicated that a portion of neuroendocrine prostate (16.7%), cervical (4.5%), ovarian (>4%), and head and neck (>3%) cancers have amplifications of DRD3. Here, DRD3 is linked to urogenital neoplasm.